Metoprolol XL 50mg + Amlodipine 5mg + Metoprolol XL 25 mg + Amlodipine 2.5mg + Metoprolol XL 50mg + Metoprolol XL 25 mg + Amlodipine 5mg

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Primary Hypertension

Conditions

Primary Hypertension

Trial Timeline

Nov 1, 2008 → Aug 1, 2009

About Metoprolol XL 50mg + Amlodipine 5mg + Metoprolol XL 25 mg + Amlodipine 2.5mg + Metoprolol XL 50mg + Metoprolol XL 25 mg + Amlodipine 5mg

Metoprolol XL 50mg + Amlodipine 5mg + Metoprolol XL 25 mg + Amlodipine 2.5mg + Metoprolol XL 50mg + Metoprolol XL 25 mg + Amlodipine 5mg is a approved stage product being developed by AstraZeneca for Primary Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00819104. Target conditions include Primary Hypertension.

What happened to similar drugs?

20 of 20 similar drugs in Primary Hypertension were approved

Approved (20) Terminated (6) Active (0)
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
Duloxetine + PlaceboEli LillyApproved
Eszopiclone + PlaceboSumitomo PharmaApproved
Eszopiclone + PlaceboSumitomo PharmaApproved
RosuvastatinAstraZenecaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00819104ApprovedCompleted

Competing Products

20 competing products in Primary Hypertension

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
33
azenosertibZentalis PharmaceuticalsPhase 2
32
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
31
Rituximab, lenalidomideCelltrionPhase 2
42
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
40
CS-3150Daiichi SankyoPre-clinical
26
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
33
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
33
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
18
Roxadustat + PlaceboAstellas PharmaPhase 3
32
Enzalutamide + ExemestaneAstellas PharmaPhase 2
35
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31